Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling

Area of Science:

• Immunology and Virology
• Pharmacology and Therapeutics
• Critical Care Medicine

Background:

• Cytokine cascade modulation is crucial for managing severe COVID-19.
• Interleukin-6 (IL-6) inhibitors are extensively studied anti-cytokine therapies.
• Understanding IL-6's dual role (protective vs. pathogenic) is key.

Purpose of the Study:

• To identify patient characteristics and biomarker thresholds for optimal IL-6 inhibitor use.
• To define precise therapeutic windows for biologics in COVID-19.
• To analyze the biological significance of IL-6 in different disease stages.

Main Methods:

• Review of observational studies, randomized controlled trials, and meta-analyses.
• Analysis of baseline patient characteristics and study outcomes.
• Evaluation of IL-6 and other biomarker predictivity at specific thresholds.

Main Results:

• IL-6 inhibitors (e.g., anti-IL-6R monoclonal antibodies) are effective in severe COVID-19.
• Optimal therapeutic window for IL-6 inhibitors defined by IL-6 levels (35-90 ng/mL), PaO2/FiO2 ratio (100-200 mmHg), CRP (120-160 mg/L), ferritin (800-1600 ng/mL), D-dimer (750-3000 ng/mL), and LDH (350-500 U/L).
• Other biologics like GM-CSF, JAK, and IL-1 inhibitors show potential in specific disease stages and patient demographics.

Conclusions:

• Targeted use of biologics based on defined therapeutic windows is essential for COVID-19 treatment success.
• Biomarker-guided therapy can optimize outcomes and inform future clinical trial recruitment.
• IL-6's role shifts from protective in early stages to pathogenic in severe/critical disease.